PTO/SB/68 (04-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	REQUEST FOR A	CCESS TO AN A	APPLICATION	UNDER 37 CFR	1.14(e)			
			In re Application	on of				
	RECEIVED		Application Number		Filed			
	DE0 1 0 2002		07-715	72	06-14-91			
,	DEC 1 8 2002	,	Art Unit	Examiner				
	File Information Unit							
	The information offic	ļ						
	Paper No. + 137							
	Assistant Commissioner fo	r Patents		,				
	Washington, DC 20231							
			,	•				
1. I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)								
	(A) referred to in:		,					
	United States Patent A	oplication Publication	n No	, page	, line,			
	United States Patent N	umber <u>640</u> 76	2/3	_, column, line	e, or			
•	an International Applica	ation which was filed	on or after Nove	mber 29, 2000 and wh	ich			
	designates the United States, WIPO Pub. No, page, line							
	(B) referred to in an applica	ation that is open to	public inspection	as set forth in 37 CFR	1.11(b) or			
	, , , , , , , , , , , , , , , , , , , ,		-	per No, page .	1			
	(-)(-)(-)(-)							
				•				
2. I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.								
Chap. 18/2, 12 18.02								
Signature Date								
Shoaidhhayour For Provise Shirt								
	Typed or printed nam	16	•	Approved bDEC 1	8 2002 (initials)			
	Unit: File Info							

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the tended to the Hour Statement of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



(12) United States Patent Carter et al.

(10) Patent No.:

US 6,407,213 B1

(45) Date of Patent:

Jun. 18, 2002

METHOD FOR MAKING HUMANIZED **ANTIBODIES**

- (75) Inventors: Paul J. Carter; Leonard G. Presta, both of San Francisco, CA (US)
- Assignee: Genentech, Inc., South San Francisco, CA (US)
- Notice: Subject to any disclaimer, the term of this (*) patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

08/146,206 (21) Appl. No.:

(2), (4) Date:

- (22) PCT Filed: Jun. 15, 1992
- (86) PCT No.: PCT/US92/05126 § 371 (c)(1),

Nov. 17, 1993 Related U.S. Application Data

- Continuation-in-part of application No. 07/715,272, filed on Jun. 14, 1991, now abandoned.
- (51) Int. Cl.⁷ C07K 16/00 (52) U.S. Cl. 530/387.3; 435/69.6; 435/69.7;
- 435/70.21; 435/91; 536/23.53; 424/133.1 435/70.21, 91, 172.2, 240.1, 240.27, 252.3, 320.1, 328; 536/23.53; 424/133.1; 530/387.3

(56)References Cited

U.S. PATENT DOCUMENTS

		and the second s
4,816,567 A	3/1989	Cabilly et al.
4,845,198 A	7/1989	Urdal et al 530/388.22
5,132,405 A	7/1992	Huston et al 530/387.3
5,225,539 A	7/1993	Winter 530/389.3
5,530,101 A	6/1996	Queen et al 530/387.3
5,558,864 A	9/1996	Bendig et al 424/133.1
5,585,089 A	12/1996	Queen et al 424/133.1
5,677,171 A	10/1997	Hudziak et al 435/7.23
5,693,762 A	* 12/1997	Queen et al 530/387.2
5,714,350 A	2/1998	Co et al 435/69.6
5,772,997 A	6/1998	Hudziak et al 424/130.1
5,821,337 A	10/1998	Carter et al 530/387.3
5,834,598 A	11/1998	Lowman et al 530/399
5,859,205 A	1/1999	Adair et al 530/387.3

FOREIGN PATENT DOCUMENTS

ΑU	85058/91 3/1992	C07K/15/12
EP	120694 10/1984	
EP	125023 A1 11/1984	
EΡ	0 239 400 * 9/1987	C12N/15/00
EP	323806 A1 7/1989	
EP	328404 A1 8/1989	A61K/39/395
EP	338745 A1 10/1989	
EP	365209 A2 4/1990	
EP	365997 A2 5/1990	
EP	368684 5/1990	
EP	403156 A1 12/1990	
EP	438310 A2 7/1991	
EP	438312 A2 7/1991	
EP	440351 A2 8/1991	
EP	0 460 167 B1 12/1991	
EP	0 519 596 A1 <u> </u> 12/1992	,

EP	0 592 106	A 1	4/1994	
EP	0 620 276		10/1994	
EP	682040	A 1	11/1995	
EP	451216	B1	1/1996	C12P/21/08
EP	432249	B1	9/1996	
GB	2 188941		10/1987	
wo	WO 87/02671		5/1987	
wo	WO 88/09344		12/1988	
wo	WO 89/01783		3/1989	
wo	WO 89/06692		7/1989	
wo	WO 89/09622		10/1989	
wo	WO 90/07861		7/1990	
wo	90/07861		* 7/1990	C12P/21/00
wo	WO 91/07492		5/1991	
wo	WO 91/07500		5/1991	
wo	WO 91/09966		7/1991	C12P/21/08
wo	WO 91/09968		7/1991	C12P/21/08
wo	WO 91/09967		11/1991	
WO	WO 92/01047		1/1992	
wo	WO 92/04380		3/1992	
wo	WO 92/04381		3/1992	
wo	WO 92/05274		4/1992	
wo	WO 92/11383		7/1992	
wo	WO 92/11018		9/1992	A61K/35/14
wo	WO 92/15683		9/1992	
wo	WO 92/16562		10/1992	
wo	WO 92/22653		12/1992	
wo	WO 93/02191		2/1993	•
wo	94/11509		5/1994	
wo	WO 94/12214		6/1994	

OTHER PUBLICATIONS

Riechmann et al. [Nature 332:323-327 (1988)].*

Queen et al. [Proc. Natl. Acad. Sci. 86:10029-10033 (1989)].*

Roitt [Immunology, published 1985, by Gower Medical Publishing Ltd. (London, England) p. 5.5].*

Tramontano et al. [J. Mol. Biol. 215:175-182 (1990)].*

"Biosym Technologies" in New Products, Chemical Design Automation 3 (Dec. 1988).

"Polygen Corporation" in New Products, Chemical Design Automation 3 (Nov. 1988).

Adair et al., "Humanization of the murine anti-human CD3 monoclonal antibody OKT3" Hum. Antibod. Hybridomas 5:41-47 (1994).

Chothia et al., "Principles of protein-protein recognition" Nature 256:705-708 (1975).

Chothia et al., "Transmission of conformational change in insulin" Nature 302:500-505 (1983).

Corti et al., "Idiotope Determining Regions of a Mouse Monoclonal Antibody and Its Humanized Versions" J. Mol. Biol. 235:53-60 (1994).

(List continued on next page.)

Primary Examiner—Anthony C. Caputa Assistant Examiner-Minh-Tam Davis (74) Attorney, Agent, or Firm-Wendy M. Lee

ABSTRACT

Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.

82 Claims, 9 Drawing Sheets